Genentech's Gazyva succeeds in phase 3 trial for primary membranous nephropathy
Source: SeekingAlpha
2026-02-17 11:20:53 ET
More on Roche
- Roche Holding AG (RHHBY) Shareholder/Analyst Presentation
- Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
- Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
- Genentech multiple sclerosis candidate fenebrutinib meets goal in late-stage trial
- ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025
Read the full article on Seeking Alpha
For further details see:
Genentech's Gazyva succeeds in phase 3 trial for primary membranous nephropathy
Astellas Pharma Inc
NASDAQ: ALPMF
ALPMF Trading
-13.02% G/L:
$13.83 Last:
646 Volume:
$13.55 Open:
ALPMF Latest News
ALPMF Stock Data
$28,999,226,915
1,808,873,137
N/A
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
